TABLE 1. Characteristics of immunocompetent adults aged ≥65 years, hospitalized with COVID-like illness,* by COVID-19 case status — IVY Network, 22 hospitals,† 18 U.S. states, September 8, 2022–November 30, 2022.
| Characteristic | No. (%) |
||
|---|---|---|---|
| Total (N = 798) | COVID-19 case-patients (n = 381) | Test-negative control patients (n = 417) | |
|
Vaccination status
| |||
| Unvaccinated |
143 (18)
|
81 (21) |
62 (15) |
| ≥2 Monovalent-only mRNA doses |
576 (72)
|
280 (73) |
296 (71) |
| Bivalent booster dose§ |
79 (10)
|
20 (5) |
59 (14) |
|
Female sex
|
442 (55)
|
210 (55) |
232 (56) |
|
Median age, yrs (IQR)
|
76 (70–83)
|
78 (71–85) |
75 (69–81) |
|
Age group, yrs
| |||
| 65–74 |
345 (43)
|
140 (37) |
205 (49) |
| ≥75 |
453 (57)
|
241 (63) |
212 (51) |
|
Race and ethnicity
| |||
| Black or African American, non-Hispanic |
118 (15)
|
52 (14) |
66 (16) |
| Hispanic or Latino, any race |
78 (10)
|
40 (11) |
38 (9) |
| White, non-Hispanic |
551 (69)
|
264 (69) |
287 (69) |
| Other race, non-Hispanic¶ |
18 (2)
|
8 (2) |
10 (2) |
| Other** |
33 (4)
|
17 (4) |
16 (4) |
|
HHS region†
| |||
| 1 |
155 (19)
|
91 (24) |
64 (15) |
| 2 |
50 (6)
|
29 (8) |
21 (5) |
| 3 |
9 (1)
|
4 (1) |
5 (1) |
| 4 |
94 (12)
|
40 (11) |
54 (13) |
| 5 |
125 (16)
|
66 (17) |
59 (14) |
| 6 |
99 (12)
|
42 (11) |
57 (14) |
| 7 |
68 (9)
|
27 (7) |
41 (10) |
| 8 |
145 (18)
|
58 (15) |
87 (21) |
| 9 |
29 (4)
|
14 (4) |
15 (4) |
| 10 |
24 (3)
|
10 (3) |
14 (3) |
|
No. of underlying medical conditions
| |||
| 0 |
38 (5)
|
15 (4) |
23 (6) |
| 1 |
172 (22)
|
91 (24) |
81 (19) |
| 2 |
243 (30)
|
115 (30) |
128 (31) |
| ≥3 |
345 (43)
|
160 (42) |
185 (44) |
| Previous Omicron infection†† | 66 (8) | 24 (6) | 42 (10) |
Abbreviation: HHS = U.S. Department of Health and Human Services.
* COVID-19–like illness was defined as including any one of the following: fever, cough, shortness of breath, new or worsening findings on chest imaging consistent with pneumonia, or hypoxemia defined as oxygen saturation (SpO2) <92% on room air or supplemental oxygen to maintain SpO2 ≥92%. For patients on chronic oxygen therapy, hypoxemia was defined as SpO2 below baseline or an escalation of supplemental oxygen to maintain a baseline SpO2.
† Hospitals by HHS region included Region 1: Baystate Medical Center (Springfield, Massachusetts) and Beth Israel Deaconess Medical Center (Boston, Massachusetts); Region 2: Montefiore Medical Center (New York, New York); Region 3: Johns Hopkins Hospital (Baltimore, Maryland); Region 4: Emory University Medical Center (Atlanta, Georgia), University of Miami Medical Center (Miami, Florida), Vanderbilt University Medical Center (Nashville, Tennessee), and Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina); Region 5: Cleveland Clinic (Cleveland, Ohio), Hennepin County Medical Center (Minneapolis, Minnesota), The Ohio State University Wexner Medical Center (Columbus, Ohio), and University of Michigan Hospital (Ann Arbor, Michigan); Region 6: Baylor Scott & White Health – Baylor Scott & White Medical Center (Temple, Texas) and Baylor Scott & White Health – Baylor University Medical Center (Dallas, Texas); Region 7: Barnes-Jewish Hospital (St. Louis, Missouri) and University of Iowa Hospitals (Iowa City, Iowa); Region 8: Intermountain Medical Center (Murray, Utah) and UCHealth University of Colorado Hospital (Aurora, Colorado); Region 9: Stanford University Medical Center (Stanford, California) and UCLA Medical Center (Los Angeles, California); and Region 10: Oregon Health & Science University Hospital (Portland, Oregon) and University of Washington (Seattle, Washington).
§ Bivalent COVID-19 mRNA booster dose recipients received ≥2 monovalent COVID-19 mRNA doses ≥2 months before their bivalent booster dose.
¶ Other race, non-Hispanic includes Asian, Native American or Alaska Native, and Native Hawaiian or other Pacific Islander; these groups were combined because of small counts.
** Self-reported race and ethnicity as other, or patients for whom information on race and ethnicity was unavailable.
†† Previous Omicron infection was defined by date of self-reported or documented previous SARS-CoV-2 infection that occurred during December 26, 2021–November 30, 2022.